scPharmaceuticals SCPH 深 沪
等待开盘 09-17 09:30:00 美东时间
5.62
+0.010
+0.18%
华盛通- 最 高5.645
- 今 开5.62
- 成交量 94.50万股
- 最 低 5.61
- 昨 收 5.61
- 总市值 2.97亿
- 52周最高 6.2799
- 市盈率 静 --
- 换手率 1.79%
- 52周最低 1.94
- 委 比 77.15%
- 总股本 5279.20万
- 历史最高 18.17
- 量 比 0.98
- 振 幅 0.62%
- 历史最低 1.94
- 每 手 1
- 风险率 0.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多华兴资本医疗与生命科技行业周报【Vol.382】
来源：华兴资本 “华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域，目...
09-01 08:30
美股大行评级 | 潜在涨幅163.16%！HIVE Digital Technologies获Roth Capital升目标价至7.5美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持HIVE Digital Technologies"买入"评级，目标价从6美元升至7.5美元；Craig-Hallum：维持Ranpak Hldgs"买入"评级，目标价从8美元升至10美元
08-27 08:32
Craig-Hallum Downgrades scPharmaceuticals to Hold, Announces $6 Price Target
Craig-Hallum analyst Chase Knickerbocker downgrades scPharmaceuticals (NASDAQ:SCPH) from Buy to Hold and announces $6 price target.
08-27 02:01
Maxim Group Downgrades scPharmaceuticals to Hold
Maxim Group analyst Naz Rahman downgrades scPharmaceuticals (NASDAQ:SCPH) from Buy to Hold.
08-26 02:57
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.
08-26 01:57
scPharmaceuticals Announces Merger with MannKind Corporation
The latest announcement is out from scPharmaceuticals ( ($SCPH) ). On August 24...
08-25 19:59
MannKind Announces Acquisition of scPharmaceuticals
An announcement from MannKind ( ($MNKD) ) is now available. On August 24, 2025,...
08-25 19:58
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MannKind to acquire scPharmaceuticals for up to $6.35 per share, diversifying its revenue and expanding into cardiorenal medicine with FUROSCIX, a treatment for edema. The deal includes a $5.35 upfront cash payment and a contingent value right (CVR) potentially adding $1.00 per share. The upfront payment represents a 36% premium to scPharmaceuticals’ VWAP, and the total consideration a 31% premium to its August 22 closing price.FUROSCIX, which ad...
08-25 11:30
scPharmaceuticals Secures 5 New USPTO Patent Allowances For SCP-111 Furosemide Formulation Ahead Of Supplemental NDA Filing
scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of
08-14 20:41
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
scPharmaceuticals Inc.近日宣布，其呋塞米配方SCP-111获得美国专利商标局五项专利授权。这些专利将补充公司现有的四项专利，进一步加强知识产权组合。SCP-111的补充新药申请预计本季度提交。首席执行官John Tucker表示，这些专利对治疗心力衰竭或慢性肾病引起的水肿至关重要，并支持下一代产品开发及市场扩展。
08-14 12:30
